中和
效力
抗体
药效学
药代动力学
体外
单克隆抗体
药理学
中和抗体
病毒学
体内
病毒
安慰剂
医学
不利影响
治疗指标
免疫学
临床试验
生物
单克隆
化学
重组DNA
分子生物学
作者
Francesco Borriello,Gavin C. K. W. Koh,Iñaki F Troconiz,Rounak Nassirpour,Lovely Goyal,Anvar Suyundikov,Akber Safder,Nicholas Robertson,Anna Allen,Andrew W. Robertson,Stephanie Straley,Pam Farmer,Denise Murphy,Eric Carlin,Kimberly P. Schmitt,Amarendra Pegu,Daria J. Hazuda,Alexandra Snyder,Dinesh P. de Alwis
标识
DOI:10.1093/infdis/jiag349
摘要
BACKGROUND: Antibodies against the SARS-CoV-2 spike receptor-binding domain provided effective COVID-19 treatment until resistant variants emerged. GB-0669 is a half-life-extended monoclonal antibody optimized using artificial intelligence. It targets the conserved spike S2 stem helix, a region subject to limited selective pressure from antibody responses induced by natural infection or vaccination. METHODS: Preclinical safety studies were conducted in cynomolgus monkeys. In the first-in-human trial, healthy adults aged 18-55 received single intravenous doses of GB-0669 or placebo in 5 ascending cohorts (100, 300, 600, 1200, and 2400 mg). Participants were monitored for 43 weeks to evaluate safety, pharmacokinetics (PK), and pharmacodynamics (PD; serum live virus neutralization). In vitro studies assessed neutralization of GB-0669 combined with antiviral drugs (remdesivir, nirmatrelvir, and molnupiravir). RESULTS: Preclinical studies revealed no safety concerns. In the clinical trial (n = 51; 36 GB-0669, 15 placebo), GB-0669 was well-tolerated without dose-limiting toxicities; all adverse reactions were mild (Grade 1 or 2). Pharmacokinetics showed dose proportionality up to 2400 mg, with a half-life of 54 days. Dose-dependent increases in serum live virus neutralization occurred at 600 and 1200 mg, with separation from placebo. The estimated neutralizing index that adjusts GB-0669 serum concentrations for its in vitro neutralizing potency supported therapeutic efficacy for 2 weeks post-administration. Finally, in vitro experiments showed improved neutralization profiles of GB-0669 in combination with antivirals. CONCLUSIONS: The data support exploring GB-0669 at 1200 mg in a Phase 2 trial for treating COVID-19 in immunocompromised individuals. The combination of GB-0669 with antiviral drugs may offer additional therapeutic benefits. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov Identifier. NCT07050511.
科研通智能强力驱动
Strongly Powered by AbleSci AI